InsiderPulse
Dashboard

RXRX

Recursion Pharmaceuticals

Health CareRussell 2000

Recursion Pharmaceuticals insider trading

Recursion Pharmaceuticals files with the SEC as a Biological Products, (No Diagnostic Substances) company headquartered in Salt Lake City, UT. Every time one of its executives or directors buys or sells the stock, the filing appears here the moment it reaches the SEC — with grants and option exercises set apart from the trades that cost the insider their own money.

From SEC filings

Recent RXRX insider transactions

4 insiders traded RXRX on the open market between Apr 22, 2026 and Sep 08, 2026 — 13 sales worth $1.3M, of which every one was pre-scheduled under a 10b5-1 plan.

Bought
—
Sold
$1.3M

13 of 13 on a 10b5-1 plan

Net
−$1.3M
Insiders
4

Open-market purchases (code P) and sales (code S) from Recursion Pharmaceuticals's own SEC Form 4 filings. Grants and option exercises are excluded — they are compensation, not decisions. Share counts are derived from the reported value and price. Verify any figure against the original filing before acting on it; this is monitoring, not advice.

Filing history last read from EDGAR on Sep 23, 2026. The live dashboard shows new filings the moment they clear.

Every RXRX Form 4 on SEC.gov

SEC Form 4 data, Q3 2024 to Q2 2026

RXRX insider trading by quarter

Between Jul 01, 2024 and Jun 30, 2026, 7 insiders traded RXRX on the open market: 0 purchases and 81 sales worth $18.8M, 80 of the sales pre-scheduled under a 10b5-1 plan. In the last four quarters alone: 0 purchases and 38 sales ($12.9M), by 5 insiders.

QuarterBoughtSold
Q2 2026—−$1.1M11 sales · all on a plan
Q1 2026—−$3.4M11 sales · all on a plan
Q4 2025—−$3.5M9 sales · all on a plan
Q3 2025—−$4.9M7 sales · 6 on a plan
Q2 2025——
Q1 2025—−$1.7M7 sales · all on a plan
Q4 2024—−$1.6M15 sales · all on a plan
Q3 2024—−$2.6M21 sales · all on a plan
Largest sale
−$2.6M of RXRX by Gibson Christopher (Chief Executive Officer · Director) on Aug 11, 2025, under a 10b5-1 plan.

Open-market transactions through Jun 30, 2026most recent first

  • Khan Najat10b5-1

    CEO and President · Director

    −$84.4K

    Jun 05, 2026

    23,588 sh · $3.58

  • Gibson Christopher10b5-1

    Director

    −$124K

    Apr 07, 2026

    40,000 sh · $3.10

  • Borgeson Blake10b5-1

    Director

    −$93K

    Apr 07, 2026

    30,000 sh · $3.10

  • Gibson Christopher10b5-1

    Director

    −$130K

    Mar 23, 2026

    40,000 sh · $3.25

  • Taylor Ben R10b5-1

    Chief Financial Officer

    −$27K

    Mar 17, 2026

    7,956 sh · $3.39

  • Khan Najat10b5-1

    CEO and President · Director

    −$94.8K

    Mar 09, 2026

    28,298 sh · $3.35

  • Borgeson Blake10b5-1

    Director

    −$588.2K

    Mar 03, 2026

    170,000 sh · $3.46

  • Gibson Christopher10b5-1

    Director

    −$138.4K

    Feb 19, 2026

    40,000 sh · $3.46

  • Taylor Ben R10b5-1

    Chief Financial Officer

    −$41.4K

    Feb 18, 2026

    13,426 sh · $3.08

  • Gibson Christopher10b5-1

    Director

    −$164.8K

    Feb 04, 2026

    40,000 sh · $4.12

  • Borgeson Blake10b5-1

    Director

    −$924K

    Feb 03, 2026

    220,000 sh · $4.20

  • Gibson Christopher10b5-1

    Director

    −$178.8K

    Jan 20, 2026

    40,000 sh · $4.47

  • Borgeson Blake10b5-1

    Director

    −$959.2K

    Jan 06, 2026

    220,000 sh · $4.36

  • Gibson Christopher10b5-1

    Director

    −$170K

    Jan 05, 2026

    40,000 sh · $4.25

  • Taylor Ben R10b5-1

    Chief Financial Officer

    −$89.4K

    Dec 29, 2025

    21,383 sh · $4.18

From SEC's quarterly Form 3, 4 and 5 data sets: code P purchases and code S sales of common stock, by the date the trade happened. Where a fund and the people who control it each report the same block, it is counted once. Trades made in the last days of Q2 2026 but filed after it closed arrive with SEC's next quarterly release.

Recursion Pharmaceuticals company record

SEC industry classification
Biological Products, (No Diagnostic Substances)
Headquarters
Salt Lake City, UT
Incorporated in
DE
Listed on
Nasdaq
SEC Central Index Key
0001601830
Previously filed as
Recursion Pharmaceuticals, LLC

Sourced from this company's own SEC submissions record. The industry label is SEC's Standard Industrial Classification, which is more specific than the Health Care sector shown above.

After insiders bought RXRX

What the stock actually did in the 90 days following each open-market purchase

Don't check RXRX — let it ping you

Get told the moment an insider moves on RXRX

Pro watches Recursion Pharmaceuticals for you and sends a Telegram ping within moments of a Form 4 clearing EDGAR — a C-suite open-market buy, a cluster, a 10b5-1 regime break — long before it reaches the press. Add RXRX to a watchlist, see each mover's benchmark-measured track record and which legendary funds hold it, and read the full filing history instead of the last 72 hours.

Track RXRX on the live dashboardFilings on SEC.gov

The live dashboard is free to open. Alerts, watchlists, full filing history and each mover's benchmark-measured track record are Pro. Monitoring, not advice.

How to read RXRX insider activity

Open-market purchase (code P)
An insider spending their own money at market price. This is the only buy code that reliably carries signal — it is a decision, not compensation.
Grants and option exercises (codes A, M)
Scheduled compensation. Most "insider buying" headlines are really this, which is why InsiderPulse weights it at a fraction of a real purchase.
Cluster buy
Two or more different insiders buying on the open market in the same window. One executive buying can mean anything; three is much harder to explain away.

Other Health Care tickers

TWSTPACBARWRIONSAXSMKRYSRAREFOLDACADPTCTMEDPDNLI
This week on the tape: who actually chose to sellThe weekly split of scheduled 10b5-1 selling vs deliberate sales, with the deciders named.

Questions

Are RXRX insiders buying or selling?
Between Apr 22, 2026 and Sep 08, 2026, 4 Recursion Pharmaceuticals insiders made no open-market purchases and 13 sales worth $1.3M, a net sale of $1.3M. 13 of the sales were pre-scheduled under a Rule 10b5-1 plan.
How much RXRX stock have insiders bought and sold in the last two years?
Between Jul 01, 2024 and Jun 30, 2026, 7 Recursion Pharmaceuticals insiders made no open-market purchases and 81 sales worth $18.8M. 80 of the sales were pre-scheduled under a Rule 10b5-1 plan. In the four quarters to Jun 30, 2026: no purchases and 38 sales ($12.9M). The largest sale was Gibson Christopher selling $2.6M on Aug 11, 2025.
What was the largest recent RXRX insider trade?
Borgeson Blake (Director) sold $158.5K of RXRX stock on Jul 07, 2026 at about $3.96 a share, under a pre-scheduled 10b5-1 plan.
When did an insider last buy RXRX shares?
No open-market purchase by a Recursion Pharmaceuticals insider appears in the filings from Apr 22, 2026 to Sep 08, 2026 — every recorded open-market transaction in that period was a sale.
Where does RXRX insider trading data come from?
From the Form 4 filings Recursion Pharmaceuticals's officers, directors and 10% owners must send the SEC within two business days of a trade. Each row on this page links to its original filing on SEC EDGAR. Share grants and option exercises are kept apart from open-market purchases and sales, because only the latter cost the insider their own money.

Get the free Insider Brief

Each weekday evening: the day's biggest open-market insider buys, cluster formations and 10b5-1 plan breaks — in plain English, with grants and routine vesting stripped out. Honest about what the data can and cannot say.

No account needed. One-click unsubscribe.